Penn Davis Mcfarland Inc. boosted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 195,819 shares of the biopharmaceutical company’s stock after buying an additional 15,193 shares during the period. Gilead Sciences accounts for 3.9% of Penn Davis Mcfarland Inc.’s portfolio, making the stock its 9th largest position. Penn Davis Mcfarland Inc.’s holdings in Gilead Sciences were worth $13,300,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in GILD. Sullivan Bruyette Speros & Blaney LLC raised its stake in shares of Gilead Sciences by 0.6% in the fourth quarter. Sullivan Bruyette Speros & Blaney LLC now owns 6,779 shares of the biopharmaceutical company’s stock worth $485,000 after buying an additional 42 shares during the last quarter. Bluestein R H & Co. raised its stake in shares of Gilead Sciences by 1.2% in the fourth quarter. Bluestein R H & Co. now owns 3,665 shares of the biopharmaceutical company’s stock worth $262,000 after buying an additional 45 shares during the last quarter. Brown Brothers Harriman & Co. raised its stake in shares of Gilead Sciences by 0.9% in the third quarter. Brown Brothers Harriman & Co. now owns 5,117 shares of the biopharmaceutical company’s stock worth $405,000 after buying an additional 46 shares during the last quarter. HighPoint Advisor Group LLC raised its stake in shares of Gilead Sciences by 0.5% in the third quarter. HighPoint Advisor Group LLC now owns 11,074 shares of the biopharmaceutical company’s stock worth $837,000 after buying an additional 51 shares during the last quarter. Finally, LBA Wealth Management LLC raised its stake in shares of Gilead Sciences by 0.4% in the fourth quarter. LBA Wealth Management LLC now owns 14,258 shares of the biopharmaceutical company’s stock worth $1,021,000 after buying an additional 60 shares during the last quarter. 74.04% of the stock is currently owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Shares of Gilead Sciences, Inc. (NASDAQ GILD) traded down 1.06% during midday trading on Friday, hitting $64.12. 10,246,580 shares of the stock traded hands. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $88.85. The company’s 50 day moving average price is $65.64 and its 200-day moving average price is $69.18. The stock has a market cap of $83.79 billion, a price-to-earnings ratio of 6.78 and a beta of 1.20.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, May 2nd. The biopharmaceutical company reported $2.20 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.18 by $0.02. Gilead Sciences had a return on equity of 76.64% and a net margin of 43.42%. The company had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.66 billion. On average, equities research analysts expect that Gilead Sciences, Inc. will post $8.20 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 29th. Shareholders of record on Friday, June 16th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 3.24%. The ex-dividend date is Wednesday, June 14th. Gilead Sciences’s dividend payout ratio is currently 21.99%.

COPYRIGHT VIOLATION WARNING: This story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/06/16/gilead-sciences-inc-gild-shares-bought-by-penn-davis-mcfarland-inc-updated-updated.html.

A number of brokerages recently issued reports on GILD. Piper Jaffray Companies reissued an “overweight” rating on shares of Gilead Sciences in a research report on Thursday, February 16th. William Blair reissued an “outperform” rating on shares of Gilead Sciences in a research report on Friday. Jefferies Group LLC reissued a “buy” rating and set a $63.00 price target on shares of Gilead Sciences in a research report on Wednesday, March 15th. Vetr raised shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $79.63 target price for the company in a report on Tuesday, March 7th. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “neutral” rating and issued a $68.00 target price (down from $70.00) on shares of Gilead Sciences in a report on Monday, March 13th. Twelve research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company’s stock. Gilead Sciences currently has an average rating of “Buy” and an average price target of $80.61.

In other news, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction that occurred on Monday, April 3rd. The stock was sold at an average price of $67.18, for a total transaction of $4,926,510.94. Following the completion of the sale, the insider now owns 3,199,969 shares in the company, valued at $214,973,917.42. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gregg H. Alton sold 5,000 shares of the stock in a transaction on Thursday, March 30th. The stock was sold at an average price of $67.48, for a total value of $337,400.00. Following the completion of the transaction, the executive vice president now owns 117,988 shares of the company’s stock, valued at approximately $7,961,830.24. The disclosure for this sale can be found here. In the last quarter, insiders sold 88,276 shares of company stock valued at $5,932,578. 1.30% of the stock is owned by company insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.